We found that afatinib potently suppressed the emergence and maintenance of ALK-rearranged NSCLC cells tolerant to alectinib or brigatinib, thus afatinib shows promise for drug repositioning to treat ALK-rearranged NSCLC patients and should be evaluated in future clinical studies. This evidence concerns the gene ALK and non-small cell lung carcinoma.